Exciting Offers Await at the 2024 Hong Kong Brands and Products Expo: Herbalgy Presents Exclusive Deals & Debuting “Yick Kee Balanced Tea Limited” Health Tea Bags!
Exclusive Discounts Up to 38% and Limited Edition Gifts HONG KONG, Dec. 4, 2024 /PRNewswire/ -- As December approaches, the highly anticipated Hong Kong Brands and Products Expo is just around the corner. Herbalgy Pharmaceutical Limited, a proud participant in this annual shopping event for many years, is excited to announce a...
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the...
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13)，jointly announce that the New Drug Application (NDA) for the combination of TYVYT®...
Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result
Patient advocates call for more support for Australian workers living with a chronic condition/s following the release of a new insights report SYDNEY, Dec. 4, 2024 /PRNewswire/ -- A new report released today has found that of the one in two Australians living with a chronic health condition/s, over a third (37%) have left a job due to their condition/s. The two...
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically meaningful reductions in inflammation and ocular pain observed as early as Day 3 Very favorable safety profile with low adverse event rate in active groups WENZHOU, China and SAN DIEGO, Dec....
ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine
First Implants of Innovative Device Completed in the United States and Australia MINNEAPOLIS, Dec. 3, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and Drug Administration (FDA)-approved Investigation Device Exemption (IDE) pivotal trial, the RELIEV-CM2 Clinical Study. The first implants of ShiraTronics neuromodulation...
Momcozy Launches ‘Love in Action’ Charity Contest to Support Mothers This Holiday Season
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- The global one-stop mother and baby brand Momcozy is thrilled to announce the launch of the "Love in Action" Charity Contest this holiday season, as part of its "Joy for All, Love for You" campaign, coinciding with Giving Tuesday. This initiative underscores the brand's commitment to spreading joy and ensuring that the love...
TraceLink Announces Grant Recipients Driving Impact Across the Globe
BOSTON, Dec. 3, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has announced the recipients of its 2024 corporate grant program. The grants have been awarded to five nonprofit organizations across the United States, EMEA, and APAC, each dedicated to unique purposes...
Milliken & Company Receives 2024 EcoVadis Gold Rating
SPARTANBURG, S.C., Dec. 3, 2024 /PRNewswire/ -- Global diversified manufacturer Milliken & Company today announced that it earned a gold rating on its 2024 EcoVadis assessment. EcoVadis provides trusted business sustainability ratings for more than 130,000 organizations representing more than 220 industries. Milliken's 2024 EcoVadis score, assessed across its chemical, textile, flooring and healthcare operations, again places the company...
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures – SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral...
